Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Investor Presentation (March 2024)
18 slides from Clearpoint Neuro's investor presentation, Mar 12, 2024
Slide 1: When Your Path Is Clear, We Point the Way
oe CLEARPOINT” “NEURO. WHEN YOUR PATH HS | WE POINT THE WAY. Nasdaq: Cel March 2024 © 2024 CLEARPOINT NEURO
Slide 2: Forward-looking statements
© 2 0 2 4 C L E A R P O I N T N E U R O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and
Slide 3: Device, Cell and Gene Therapy-Enabling Company
CLEARPOINT We Are a Device, Cell and Gene Therapy- Enabling Company, Offering Precise Navigation to the Brain and Spine We Uniquely Provide Both Established Clinical Products as well as Pre-Clinical Development Services for Controlled Drug and Device Delivery 4 CLEARPOINT NEURO
Slide 4: • • • • • • • • • • • *Including owned and
• • • • • • • • • • • *Including owned and licensed patents 4
Slide 5: The ClearPoint Neuro Navigation System
The ClearPoint® Neuro Navigation System Leverage live MR Imaging to Decide, Guide, and Confirm with sub-millimetric accuracy Pre-Plan Trajectory and Automatically Guide Confirm Quality of Delivery Decide Entry Point Precision Adjustments Prior to Into Permanent Record Insertion *, CLEARPOINT ) 2024
Slide 6: ClearPoint product components
ClearPoint Neuro Navigation Software v.2.2 ClearPoint Array® Software v.1.2 ClearPoint Maestro® Brain Model Inflexion® Head Fixation Frame ClearPoint Prism® Neuro Laser Therapy System MRI Monitor Multi-Positional Head Fixation Frame Accessory Kit (4Fr, 5Fr, and 7Fr Available) SmartFrame Array® Kit C
Slide 7: Revenue history and 2024 guidance
7 (A) (B) (D) © 2 0 2 4 C L E A R P O I N T N E U R O (A) Estimated and subject to revision (B) For the quarter ended December 31, 2023 (C) Including owned and licensed patents (D) For the Trailing Twelve Months (TTM) (C) $3.6 Revenue Guidance $4.6 $5.7 $7.4 $7.4 $11.2 $12.8 $16.3 $20.6 $24.0 $28.0
Slide 8: Facilities and quality systems
© 2 0 2 1 C L E A R P O I N T N E U R O 8 • 1,500 sq. ft Class 8 Clean Room with Expansion Capability • 1,300 sq. ft Dedicated R&D Lab Space • ISO 13485/MDSAP/EU MDR Certified Quality System • Successful Audit Outcomes from Global Regulatory Bodies and Pharma • Training Facility with over 100 Surgeo
Slide 9: 75+ Global Centers
Company 75+ Global Centers Hackensack University Medical Center Henry Ford Health Hospital of University Pennsylvania Houston Methodist Hospital INOVA Fairfax JFK University Medical Center Johns Hopkins University Kaleida Health Kettering Health Loma Linda University Health Lucile Packard Children’s
Slide 10: Compatible with all major MRI scanners and partners
© 2 0 2 4 C L E A R P O I N T N E U R O 10 VISUALASE ClearPoint Navigation is Compatible with all Major Diagnostic and Intraoperative MRI Scanners …with 50+ industry and academic partners *In approved clinical trials and preclinical studies.
Slide 11: Addressable indications and market opportunity
Parkinson’s Disease 1,000,0001 60,0001 • $270 M - $1.35 B Drug Resistant Epilepsy 1,000,0002 11,0003 • $49.5 M - $198 M Refractory Essential Tremor 3,500,0004 60,0005 $180 M - $1.08 B Brain Tumors (n=3)6 35,0007,8 13,3007,8 $33.3 M - $300 M Severe Obsessive-Compulsive Disorder 500,0009,10 10,0009,10
Slide 12: Citations and footnotes
© 2 0 2 4 C L E A R P O I N T N E U R O 12 1. “Parkinson’s Disease Statistics,” Parkinson’s News Today, https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older 2. Neurona Therapeutics. (2021 November 4). Neurona Therapeutic
Slide 13: 4 Pillar Growth Strategy by 2025
NEW THERAPY DEVICES NEURO NAVIGATION FOR DBS BIOLOGICS & DRUG DELIVERY 20252024 4 Pillar Growth Strategy by 2025 Development Pipeline Over the Next Two Years Full Market Release for PRISM Neuro Laser Integrate Tumor Segmentation Software Activate Maestro Ablation Coverage & A.I. Predictive Modeling
Slide 14: Development pipeline over the next two years
© 2 0 2 4 C L E A R P O I N T N E U R O 14 Radially Branching Cell therapy Devices ClearPoint Orchestra Head Fixation Frame Spinal Infusion Anchoring Devices PRISM 3.0 T & 1.5 T Compatible Systems (1.5 T Compatibility not yet FDA Cleared) Array 1.2 Parallel Trajectory Tumor Feature *Biologics & Drug
Slide 15: ClearPoint Maestro Brain Model
© 2 0 2 4 C L E A R P O I N T N E U R O 15 • FDA Cleared, Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects • Auto-Segmentation for Device Targeting • Direct Navigation in Clinical Trials for Drug Delivery • Longitudinal Comparison for Pharma Trial
Slide 16: Investment highlights
© 2 0 2 4 C L E A R P O I N T N E U R O 16 Unique platform technology with 10+ years of commercial experience enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders Large, growing number of customer and partner sites of 75+ leading Neurosurgery
Slide 17: Slide 17
Slide 18: ClearPoint Neuro
CLEARPOINT NEURO
ClearPoint Neuro — Investor Presentation (March 2024) on 6ix